Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Camrelizumab by Jiangsu Hengrui Medicine for Nasopharyngeal Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Nasopharyngeal Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...
Camrelizumab by Jiangsu Hengrui Medicine for Rectal Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Rectal Cancer. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
Camrelizumab by Jiangsu Hengrui Medicine for Metastatic Melanoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Melanoma. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...